IDP Pharma, in collaboration with Carlos III Research Institute (ISCIII) and Hospital 12 de Octubre in Madrid, has published a study in the journal Neurotherapeutics (https://link.springer.com/article/10.1007/s13311-021-01176-6) which reveals that a new experimental drug, IDP-410, directly engages the key oncoprotein N-MYC and reduces the growth of glioblastomas in animal models. The Company expects to develop further IDP-410 to bring a novel therapy to patients which currently lack treatment options.
IDP Pharma will present at the Annual Meeting of the American Association for Cancer Research (June 22-24) its first in class c-Myc inhibitor program, expected to enter clinical trails in 2021.
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research, clinical studies and highlights the work of the best minds in research and medicine from institutions all over the world.
IDP Pharma has closed today a 2M€ private funding round. The company will allocate the funding to start clinical activities of IDP-121 (solid and haem tumors), to complete the formulation of IDP-233 (neuroendocrine tumors) and to exploit its technological platform (IDP Platform).
The company has received further support from RETOS public program (1M€) to advance innovative research in collaboration with CIMA and Univertisy of Navarra.
- ISBN: 9780128163481
- Elsevier: https://www.elsevier.com/books/intrinsically-disordered-proteins/salvi/978-0-12-816348-1
Intrinsically Disordered Proteins: Dynamics, Binding, and Function thoroughly examines and ties together the fundamental biochemical functions of intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs), including signaling, binding, and regulation, with the methodology for their basic and applied study, including drug design and therapeutic intervention.
Intrinsically Disordered Proteins provides students and researchers in biochemistry, molecular biology, and applied microbiology with a comprehensive and updated discussion of the complex dynamics of IDPs and IDRs.
CHAPTER 9 Perspectives on drug discovery strategies based on IDPs (Contributed by IDP Pharma)
Bio€quity 2019, the most important biopharmaceutical investor conference in Europe, will take place in Barcelona for the first time on May 20-21, 2019. IDP Pharma will attend The meeting and present the company to investors. Organized by BioCentury and EBD Group is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
Bio€quity Europe has showcased more than 800 leading European companies to thousands of investment and pharma business development professionals.
IDP Pharma will attend The BIO-Spain in Sevilla (September 25th-27th, 2018). BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.000) and companies participating (+800).
IDP Pharma will attend The BIO International Convention in Boston (4-7 June 2018), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders, exposure to industry though-leaders, and unparalleled networking opportunities with 16,000+ attendees from 74 countries. Hope yo see you there!
IDP Pharma will attend the Annual Meeting of the American Association for Cancer Research (14 -18 Apr 2018). The Meeting will take place at McCormick Place North/South in Chicago , Illinois USA. AACR 2018, Annual Meeting of the American Association for Cancer Research is going to be dealing with Medical, Health Care, Oncology and Cancer.
IDP Pharma will attend next 11th Annual European Life Sciences CEO Forum & Exhibition. This event is being held on 26th-27th February 2018 at the Hilton Zurich Airport Hotel, Switzerland, and organized by Sachs Associates. IDP Pharma will be also one of the presenting companies.
This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. It is expected over 350 delegates and 70+ presenting companies. Event’s networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive. We hope to see you there!
IDP Pharma has closed a 2,5M€ investment round. The company will allocate the capital to complete the preclinical development of its first product, push forward its new neuroendocrine tumor program and to exploit its technological platform (IDP platform).
IDP Pharma and BCN Peptides has entered a collaboration for the development of peptidomimetics. IDP Pharma will use its technology, IDP-Platform , to design peptidomimetics with target-specificity, intrinsic cell permeability properties and enhanced stability to target intra cellular proteins. BCN Peptide will optimize the synthesis and scale up the lead compounds.
IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme «Nuclis d’Innovació Tecnológica».
IDP Pharma will attend next BIO-Europe spring, Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Barcelona from 20-22 March 2017.
IDP Pharma has closed a 1,5M€ seed investment round. The private funding adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ) in collaboration with Leitat, University of Salamanca (FICUS) and BCN Peptides. The company will allocate the capital to advance the preclinical development of its first product for cancer treatment and to continue developing its technology: IDP-Platform.
IDP Pharma will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you will access over 2,500 CEO’s from leading biotech companies.
IDP Pharma has closed its first investment round. The funds raised will allow the company to develop its technology and deliver first active compounds against an IDP, a novel class of therapeutic targets.
IDP Pharma has stablished its headquarters at the Parc Científic de Barcelona (PCB).
The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences, with state-of-the-art facilities for drug discovery.